Submit Manuscript  

Article Details


Structure-based Drug Design Strategies in the Development of Small Molecule Inhibitors Targeting Bcl-2 Family Proteins

[ Vol. 17 , Issue. 8 ]

Author(s):

Zhe Yin, Donglin Yang, Jun Wang and Yuequan Jiang*   Pages 943 - 953 ( 11 )

Abstract:


Proteins of B-cell lymphoma (Bcl-2) family are key regulators of apoptosis and are involved in the pathogenesis of various cancers. Disrupting the interactions between the antiapoptotic and proapoptotic Bcl-2 members is an attractive strategy to reactivate the apoptosis of cancer cells. Structure-based drug design (SBDD) has been successfully applied to the discovery of small molecule inhibitors targeting Bcl-2 proteins in past decades. Up to now, many Bcl-2 inhibitors with different paralogue selectivity profiles have been developed and some were used in clinical trials. This review focused on the recent applications of SBDD strategies in the development of small molecule inhibitors targeting Bcl-2 family proteins.

Keywords:

Bcl-2 family proteins, apoptosis, cancer, structure-based drug design strategy, co-crystal structure, small molecule inhibitors.

Affiliation:

Thoracic Surgery Department, Chongqing University Cancer Hospital, Chongqing 400030, International Academy of Targeted Therapeutics and Innovation, Chongqing University of Arts and Sciences, Chongqing 402160, International Academy of Targeted Therapeutics and Innovation, Chongqing University of Arts and Sciences, Chongqing 402160, Thoracic Surgery Department, Chongqing University Cancer Hospital, Chongqing 400030

Graphical Abstract:



Read Full-Text article